OPRX250117P17500
- 0.00
- 0.000.00%
OptimizeRx Newsroom
OptimizeRx CEO William Febbo Resigns, Leadership Transition Planned
OptimizeRx Shares Are Trading Lower After RBC Capital Downgraded the Stock From Outperform to Sector Perform and Cut Its Price Target From $7 to $6.
RBC Capital Downgrades OptimizeRx(OPRX.US) to Hold Rating, Cuts Target Price to $6
RBC Downgrades OptimizeRx to Sector Perform From Outperform, Cuts Price Target to $6 From $7
Is There An Opportunity With OptimizeRx Corporation's (NASDAQ:OPRX) 49% Undervaluation?
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Stifel Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $8
B.Riley Financial Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $13
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $8
Optimistic Buy Rating for OptimizeRx Amid Leadership Transition and Strong Financial Outlook
OptimizeRx Names Stephen Silverstro as Interim CEO, Sees FY24 Revenue At High End of Guidance Range
Express News | OptimizeRx Corp: Reaffirms Its Financial Guidance for Full Year 2024
Press Release: OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO
Express News | OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO
Stephens Maintains OptimizeRx(OPRX.US) With Hold Rating, Cuts Target Price to $5.5
The Analyst Verdict: OptimizeRx In The Eyes Of 6 Experts
Express News | OptimizeRx Corp : Stephens Initiates Coverage With Equal Weight Rating; Target Price $5.50
OptimizeRx Initiated With an Equal Weight at Stephens
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $11
Analysts Conflicted on These Healthcare Names: OptimizeRx (OPRX) and Universal Health (UHS)